The effect of drug consultation center guidance on contraceptive use among women using isotretinoin: A randomized, controlled study

Journal of Women's Health

Volumn 17, Issue 4, 2008, Pages 579-584

  Tsur, Lilach ^a   Kozer, Eran ^a   Berkovitch, Matitiahu ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ISOTRETINOIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDOM; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR;

ACNE VULGARIS; ADOLESCENT; ADULT; CLINICAL PHARMACY INFORMATION SYSTEMS; CONTRACEPTIVE AGENTS; DERMATOLOGIC AGENTS; FEMALE; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; ISOTRETINOIN; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; REFERRAL AND CONSULTATION; TERATOGENS;

EID: 43049139546     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0623     Document Type: Article

References (19)

1. Isotretinoin. In: Briggs G, Freeman R, Yaffe S, eds. Drugs in pregnancy and lactation, 7th ed. Philadelphia: Lippincot Williams & Wilkins, 2005:862.
2. Schaefer C, Peters P. Retinoids for acne and psoriasis therapy. In: Schaefer C, ed. Drugs during pregnancy and lactation. Amsterdam: Elsevier, 2001:109.
3. Benke PJ. The isotretinoin teratogen syndrome. JAMA 1984;251:3267.
4. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985;313:837.
5. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984;28:6.
6. Chan A, Hanna M, Abbott M, Keane RJ. Oral retinoids and pregnancy. Med J Aust 1996;165:164.
7. Pastuszak A, Koren G, Rieder MJ. Use of the retinoid pregnancy prevention program in Canada: Patterns of contraception use in women treated with isotretinoin and etretinate. Reprod Toxicol 1994;8:63.
8. Nulman I, Berkovitch M, Klein J, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: Implications for fetal safety. J Clin Pharmacol 1998;38:926.
9. Abroms L, Maibach E, Lyan-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006;3:e483.
10. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995;333:145.
11. Honein MA, Paulozzi LJ, Erickson JD. Continued occurrence of Accutane exposed pregnancies. Teratology 2001;64:142.
12. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin exposed pregnancies: Evaluation of the Accutane SMART program. Arch Dermatol 2005;141:563.
13. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med 2002;347:1087.
14. Owen L. Impact of a telephone helpline for smokers who called during a mass media campaign. Tobacco Control 2000;9:148.
15. Franklin VL, Waller A, Pagliari C, Greene SA. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes. Diabet Med 2006;23:1332.
16. Boucher N, Beaulac-Baillargeon L. Pregnancy prevention among women taking isotretinoin. Failure to comply with the recommendations. Can Fam Physician 2006;52:339.
17. Robertson J, Polifka JE, Avner M, et al. A survey of pregnant women using isotretinoin. Birth Defects Res A Clin Mol Teratol 2005;73:881.
18. Iuliano AD, Speizer IS, Santelli J, Kendall C. Reasons for contraceptive nonuse at first sex and unintended pregnancy. Am J Health Behav 2006;30:92.
19. Malovizky D, Lavi B, Modan B. A reduction in the number of unwanted pregnancies among female army draftees through a controlled intervention. Fertil Steril 1997;68:435.